An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening
about
Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)Hepatitis B virus management to prevent reactivation after chemotherapy: a review.Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center.Risk of Reverse Seroconversion of Hepatitis B Virus Surface Antigen in Rituximab-Treated Non-Hodgkin Lymphoma Patients: A Large Cohort Retrospective Study.Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable.Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.Giving rituximab in patients with occult or resolved hepatitis B virus infection: are the current guidelines good enough?Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders.Antiviral therapies for managing viral hepatitis in lymphoma patients.Screening for viral hepatitis prior to rituximab chemotherapy.The impact of hepatitis B virus (HBV) infection on clinical outcomes of patients with diffuse large B-cell lymphoma.Case report: detection of a hepatitis B surface antigen variant emerging in an elderly patient after an ischemic cerebral vascular accident.
P2860
Q26801716-70B4D685-F5E8-4012-A219-9498140CC276Q34397738-D5FA0681-97DF-4EC1-AC77-8B5535C632C7Q35037621-B15C1F55-31E8-416C-95FF-8CD993D1D877Q36195013-71ACC76D-45E4-4B8D-9742-B0C7C1E1F5BDQ36311839-B446F788-82BB-498C-9795-74DB7C7D2F1FQ38218566-8A9FE247-B1CE-45BA-941D-3253F1A44A05Q38397403-27BED4E0-C345-43F3-9DCC-099A28EFC851Q38810735-1EA5ED55-E7CA-42A1-9118-332AF623E232Q38989625-4C326729-9177-4506-9EA2-A8B4A5B72617Q40993578-3D9E4CD5-B0CE-492B-9CBB-E56D1A81A307Q41107280-8E8B7536-AC13-4F87-A8D7-B78899A9EFE9Q48329633-D6B7EA17-B34B-4E38-AB12-A781E7B32D3A
P2860
An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
An argument for the universal ...... erience of hepatitis screening
@ast
An argument for the universal ...... erience of hepatitis screening
@en
type
label
An argument for the universal ...... erience of hepatitis screening
@ast
An argument for the universal ...... erience of hepatitis screening
@en
prefLabel
An argument for the universal ...... erience of hepatitis screening
@ast
An argument for the universal ...... erience of hepatitis screening
@en
P2093
P2860
P1433
P1476
An argument for the universal ...... erience of hepatitis screening
@en
P2093
Christopher Leung
Gareth Burns
William Sievert
P2860
P304
P356
10.1634/THEONCOLOGIST.2010-0182
P50
P577
2011-04-04T00:00:00Z